Form 8-K - Current report:
SEC Accession No. 0001347178-21-000025
Filing Date
2021-07-28
Accepted
2021-07-28 16:08:01
Documents
14
Period of Report
2021-07-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vnda-20210728.htm   iXBRL 8-K 45457
2 EX-99.1 vnda8-k7282021exhibit991.htm EX-99.1 109984
6 vandaq32019earningsca_imag.jpg GRAPHIC 49643
  Complete submission text file 0001347178-21-000025.txt   378258

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20210728.xsd EX-101.SCH 1963
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20210728_lab.xml EX-101.LAB 24993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20210728_pre.xml EX-101.PRE 13226
7 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20210728_htm.xml XML 11719
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 211122613
SIC: 2834 Pharmaceutical Preparations